Announcement on Receipt of Drug Registration Acceptance Notice
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
Hunan Nucien Pharmaceutical Co. Ltd. announced the receipt of a drug registration acceptance notice for a new product.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Hunan Nucien Pharmaceutical Co. Ltd. on 6ix
Earlier from Hunan Nucien Pharmaceutical
- Announcement on Progress in the Strategic Restructuring of Controlling Shareholders
- Announcement on Obtaining Drug Registration Certificate for Levosalbutamol Hydrochloride Nebuliser Solution
- Announcement on Voluntary Disclosure of Phase III Clinical Trial of Peramivir Inhalation Solution Reaching Prespecified Primary Endpoint
- Announcement on Receiving the Prior Notice of Administrative Penalty
- Announcement on Progress in Transfer of Partial Accounts Receivable and Related Party Transactions
Later from Hunan Nucien Pharmaceutical
- Announcement on Implementing Cancellation of Repurchased Shares and Share Changes
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
- Announcement on Reduction of Registered Capital, Amendment of the Articles of Association, and Completion of Industrial and Commercial Registration Changes
- Announcement on the Receipt of Warning Letters by the Company and Relevant Responsible Persons
Follow Hunan Nucien Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Nucien Pharmaceutical